FMP
NASDAQ
1.4 USD
0.18 (12.86%)
Dr. Randall C. Schatzman Ph.D.
Healthcare
Biotechnology
https://www.boltbio.com
NASDAQ
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also develo...
0001641281
US0977021049
097702104
900 Chesapeake Drive
650 665 9295
US
100
Feb 5, 2021
0001641281
NASDAQ
Biotechnology
Healthcare
097702104
US0977021049
US
1.4
0.93
119.21k
53.38M
-
0.84-2.03
-0.05
-
-
-
-
-0.77
-
https://www.boltbio.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.